CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED) - EUR (€) € in Thousands	3 Months Ended
	Mar. 31, 2020	Mar. 31, 2019
Revenue
Research and Development support	€ 17	€ 0
Grants	255	0
Total revenue	272	0
Expenses
Research and development	322	215
General and administrative	325	278
Other	106	66
Total expenses	753	559
Operating loss	(481)	(559)
Interest expense	675	666
Loss before income tax provision	(1,156)	(1,225)
Income tax provision	(8)	(3)
Net loss	(1,164)	(1,228)
Other comprehensive income
Foreign currency translation adjustment	7	5
Comprehensive loss	€ (1,157)	€ (1,223)
Basic and diluted loss per share	€ (0.00)	€ (0.00)
Weighted average number of shares used in per share calculations	303,757,622	303,757,622